Top

Published in:

01-01-2019 | Understanding the Disease

Understanding central nervous system efficacy of antimicrobials

Authors: Pierre Tattevin, Tom Solomon, Matthijs C. Brouwer

Published in: Intensive Care Medicine | Issue 1/2019

Excerpt

The requirements for antimicrobial treatment to reach the central nervous system (CNS) are of maximal importance, for two major reasons: (i) the brain is an immuno-privileged site, with virtually no leukocytes in the brain parenchyma or cerebrospinal fluid (CSF) at baseline; (ii) the blood–brain barrier (BBB) drastically reduces the diffusion of antimicrobials into the CNS [1]. Treatment of CNS infections has been a major area of research since the discovery of the first antimicrobials. Treatment regimens recommended for encephalitis [2, 3], meningitis [4], and brain abscess [5], have to comply with the pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of available antibacterial, antiviral, antifungal, and antiparasitic agents [6]. Due to the numerous constraints created by the BBB, therapeutic options are quite limited, so that current practices for treatment of CNS infections are remarkably similar worldwide, with much less heterogeneity than for other major infectious diseases (e.g. pneumonia, abdominal, or skin and skin structure infections). This paper summarizes the main parameters that must be taken into account to ensure efficacy of antimicrobial agents in the CNS, with an emphasis on antibacterial drugs. …

Available only for authorised users

Nau R, Sorgel F, Eiffert H (2010) Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23(4):858–883CrossRefPubMedPubMedCentral

Stahl JP, Azouvi P, Bruneel F, De Broucker T, Duval X, Fantin B et al (2017) Guidelines on the management of infectious encephalitis in adults. Med Mal Infect 47(3):179–194CrossRefPubMed

Gould EA, Solomon T (2008) Pathogenic flaviviruses. Lancet 371(9611):500–509CrossRefPubMed

van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR (2012) Advances in treatment of bacterial meningitis. Lancet 380(9854):1693–1702CrossRefPubMed

Sonneville R, Ruimy R, Benzonana N, Riffaud L, Carsin A, Tadie JM et al (2017) An update on bacterial brain abscess in immunocompetent patients. Clin Microbiol Infect 23(9):614–620CrossRefPubMed

Nau R, Seele J, Djukic M, Eiffert H (2018) Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections. Curr Opin Infect Dis 31(1):57–68CrossRefPubMed

Lutsar I, McCracken GH Jr, Friedland IR (1998) Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 27(5):1117–1127 (quiz 1128-1119) CrossRefPubMed

Saunders NR, Dreifuss JJ, Dziegielewska KM, Johansson PA, Habgood MD, Mollgard K et al (2014) The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history. Front Neurosci 8:404CrossRefPubMedPubMedCentral

Paris MM, Hickey SM, Uscher MI, Shelton S, Olsen KD, McCracken GH Jr (1994) Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 38(6):1320–1324CrossRefPubMedPubMedCentral

10.

Lutsar I, Friedland IR (2000) Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 39(5):335–343CrossRefPubMed

11.

Nau R, Zysk G, Thiel A, Prange HW (1993) Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man. Eur J Clin Pharmacol 45(5):469–475CrossRefPubMed

12.

Ichie T, Urano K, Suzuki D, Okada T, Kobayashi N, Hayashi H et al (2015) Influence of cerebral fluid drainage on the pharmacokinetics of vancomycin in neurosurgical patients. Pharmazie 70(6):404–409PubMed

13.

Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Michael Scheld W et al (2017) 2017 Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis 64(6):e34–e65CrossRefPubMedPubMedCentral

14.

Nau R, Djukic M, Spreer A, Ribes S, Eiffert H (2015) Bacterial meningitis: an update of new treatment options. Expert Rev Anti Infect Ther 13(11):1401–1423CrossRefPubMed

15.

Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL et al (2017) Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci 20(8):1172–1179CrossRefPubMedPubMedCentral

16.

Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK (2018) Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Deliv 25(1):307–320CrossRefPubMedPubMedCentral

Title: Understanding central nervous system efficacy of antimicrobials
Authors: Pierre Tattevin
Tom Solomon
Matthijs C. Brouwer
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 1/2019
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-018-5270-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Understanding central nervous system efficacy of antimicrobials

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

In memoriam: Professor Timothy William Evans

Fluid administration for acute circulatory dysfunction using basic monitoring: narrative review and expert panel recommendations from an ESICM task force

Early extubation followed by immediate noninvasive ventilation vs. standard extubation in hypoxemic patients: a randomized clinical trial

“What’s new?”

Clarification of errors in Abbas et al.’s conflict of interest narrative review

Her ICU bed